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Introduction {#sec005}
============

Endovascular aneurysm repair (EVAR) has become the primary choice of treatment for abdominal aortic aneurysms (AAAs) in suitable patients \[[@pone.0170600.ref001]\]. EVAR always has better short-term outcomes compared with open repair \[[@pone.0170600.ref002],[@pone.0170600.ref003]\]. Aortic endograft occlusion, migration, and endoleaks are known complications after EVAR \[[@pone.0170600.ref004]\], among which endoleaks are the most frequent. Types I and III endoleaks require urgent intervention to relieve aneurysm re-pressurization \[[@pone.0170600.ref005],[@pone.0170600.ref006]\]. Type II endoleaks are caused by backflow of collateral arteries into the aneurysm sac, with an occurrence rate of 10.2% after EVAR \[[@pone.0170600.ref007]\]. Type II endoleaks do not exert any immediate adverse effects. However, persistent type II endoleaks are believed to be associated with increased sac pressure and cause adverse outcomes and even aneurysm rupture \[[@pone.0170600.ref008]\].

Various studies assessed risk factors for type II endoleaks following EVAR \[[@pone.0170600.ref009]--[@pone.0170600.ref011]\]. Potential correlations may exist between preoperative characteristics and development of type II endoleaks \[[@pone.0170600.ref009]\]. A patent inferior mesenteric artery (IMA) and the number of patent lumbar arteries have been investigated as risk factors for type II endoleaks \[[@pone.0170600.ref010],[@pone.0170600.ref011]\]. However, no previous systematic review has concentrated on this topic. Hence, the primary objective of the present systematic review and meta-analysis was to determine the current evidence on risk factors for the onset of type II endoleaks. This review concentrated on nonclinical risk factors, such as sex and age, preoperative comorbidities, and aortic anatomy. Moreover, we intended to report the updated pooled prevalence of type II endoleaks after EVAR.

Methods {#sec006}
=======

Search strategy and study selection {#sec007}
-----------------------------------

Relevant publications were identified by searching the following database: MEDLINE (from Jan 1, 1950, to June 30, 2016) ([S1 File](#pone.0170600.s001){ref-type="supplementary-material"}), Scopus (from 1966 to June 30, 2016), and EMBASE (from 1966 to June 30, 2016). The terms "type II endoleak" or "type 2 endoleak," "endovascular," and "aneurysm" were searched. The references cited in published original and review articles were searched to identify additional studies. The search was limited to human adults and publications in English. Subsequently, two authors (Q.G. and X.D.) independently reviewed the title and abstract of the studies identified in the search to exclude those that did not answer the research question of interest in accordance with prespecified inclusion and exclusion criteria. Records extracted by the initial search were screened, and potentially relevant papers were retrieved and examined in detail. Duplicate publications and case reports were also excluded. Whenever publications of overlapping populations were available, the publication with the most complete and relevant set of data was chosen.

We identified studies in accordance with the following inclusion criteria: (1) participants: human adults (minimum of 18 years of age) with abdominal aortic aneurysm; (2) intervention: EVAR; (3) comparison: patients with potential risk factors versus patients without potential risk factors resulting in type II endoleaks; and (4) sufficient data were available for estimating an odds ratio (OR) with confidence interval (CI).

Data abstraction and quality assessment {#sec008}
---------------------------------------

Two authors (B.H. and Y.M.) extracted relevant data independently, including the first author's name, study year, study region, study design, number of type II endoleaks, number of reintervention for type II endoleaks, duration of follow-up, and potential risk factor for type II endoleaks \[including age, sex, smoking, diabetes, hypertension, hyperlipidemia, chronic renal insufficiency, chronic obstructive pulmonary diseases (COPD), polytrafluoroethylene-based endografts, anticoagulants, antiplatelet, patent inferior mesenteric artery, maximum aneurysm diameter, and number of patent lumbar arteries\]. Conflicts in data abstraction were resolved through consensus by referring back to the original article. The methodological quality of the studies was assessed by two authors (D.Y. and Y.Y.) independently using the Newcastle--Ottawa scale \[[@pone.0170600.ref012]\]. Quality was calculated on the basis of the following three aspects of study design: patient selection, comparability of study groups, and exposure and outcome of study participants. Studies that scored 5 or greater were considered high quality, whereas those that scored 4 and below were considered low quality.

Statistical analysis {#sec009}
--------------------

Statistical analyses were performed with Stata 12.0 software (StataCorp LP, College Station, Texas, USA). Dichotomous variables were analyzed by estimating the odds ratio (OR) with a 95% confidence interval (95% CI), whereas continuous variables were analyzed using the weighted mean difference with a 95% CI. Statistical heterogeneity between studies was assessed using the *I*^2^ measure. I^2^ \> 50% was considered to indicate high statistical heterogeneity. If no heterogeneity was found, a fixed effect model based on the Mantel and Haenszel estimator was used; otherwise, a random effect model based on the DerSimonian and Laird estimator was used \[[@pone.0170600.ref013]\]. Several characteristics were identified to analyze their effect on the prevalence of type II endoleaks. Categorical characteristics were treated as moderators, and effectiveness was compared across subgroups formed by year of publication (before 2010 vs. 2011--2016), surveillance test (with categories: CTA vs. others), and study setting (retrospective vs. prospective). Egger's and Begg's tests were performed to assess publication bias \[[@pone.0170600.ref014]\]. For all statistical analyses, except heterogeneity and publication bias, p \< 0.05 was regarded to indicate statistical significance, and all tests were two-sided. The present systematic review was conducted and reported in accordance with the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses ([S2 File](#pone.0170600.s002){ref-type="supplementary-material"}) \[[@pone.0170600.ref015]\].

Results {#sec010}
=======

Study characteristics and methodological quality {#sec011}
------------------------------------------------

From the 504 studies identified using our search strategy, 73 potentially relevant articles were retrieved and assessed for eligibility. In total, 45 papers were included in this review \[[@pone.0170600.ref008]--[@pone.0170600.ref011],[@pone.0170600.ref016]--[@pone.0170600.ref056]\], with 15 included in the meta-analysis \[[@pone.0170600.ref008],[@pone.0170600.ref009],[@pone.0170600.ref028],[@pone.0170600.ref032]--[@pone.0170600.ref034],[@pone.0170600.ref037],[@pone.0170600.ref038],[@pone.0170600.ref045]--[@pone.0170600.ref048],[@pone.0170600.ref050],[@pone.0170600.ref055],[@pone.0170600.ref056]\]. The flow diagram summarizing the study identification and selection is shown in [Fig 1](#pone.0170600.g001){ref-type="fig"}. The characteristics of the included studies are reported in [Table 1](#pone.0170600.t001){ref-type="table"}. The methodological quality of the included studies for meta-analysis is summarized in [S3 File](#pone.0170600.s003){ref-type="supplementary-material"}. All of the studies enrolled for meta-analysis were of high quality.

![PRISMA flow chart for the review.](pone.0170600.g001){#pone.0170600.g001}

10.1371/journal.pone.0170600.t001

###### Characteristics of included studies.

![](pone.0170600.t001){#pone.0170600.t001g}

  Studies                                                                             Country      Study design    No. of patients   Type II endoleaks   types of endoleaks   Reintervention   Follow-up (months)   Surveillance test
  ----------------------------------------------------------------------------------- ------------ --------------- ----------------- ------------------- -------------------- ---------------- -------------------- -------------------
  Chuter 2001\[[@pone.0170600.ref016]\]                                               USA          retrospective   114               9                   Any                  n.s.             n.s.                 CTA
  Haulon 2001\[[@pone.0170600.ref017]\]                                               France       retrospective   60                18                  Any                  n.s.             13.3                 CTA/MRI
  Liewald 2001\[[@pone.0170600.ref018]\]                                              Germany      retrospective   160               13                  Any                  n.s.             n.s.                 CTA
  Buth 2002\[[@pone.0170600.ref019]\][\*](#t001fn001){ref-type="table-fn"}            Netherland   retrospective   3529              240                 Any                  53               n.s.                 CTA
  Parent 2002\[[@pone.0170600.ref020]\]                                               USA          retrospective   83                36                  Any                  3                20.7                 CTA
  Solis 2002\[[@pone.0170600.ref021]\]                                                USA          retrospective   119               14                  Any                  10               18.2                 CTA
  Tuerff 2002\[[@pone.0170600.ref022]\]                                               USA          prospective     130               22                  Any                  n.s.             15.7                 CTA
  Faries 2003\[[@pone.0170600.ref023]\]                                               USA          retrospective   597               16                  Any                  n.s.             24.5                 CTA
  Farner 2003\[[@pone.0170600.ref024]\]                                               USA          retrospective   63                9                   Any                  n.s.             12                   CTA
  Kasirajan 2003\[[@pone.0170600.ref025]\]                                            USA          retrospective   104               8                   Any                  n.s.             n.s.                 CTA
  Carpenter 2004\[[@pone.0170600.ref026]\]                                            USA          prospective     227               21                  Any                  8                n.s.                 CTA
  Steinmetz 2004\[[@pone.0170600.ref027]\]                                            USA          retrospective   486               90                  Any                  4                21.7                 CTA
  Van Marrewijk 2004\[[@pone.0170600.ref028]\][\*](#t001fn001){ref-type="table-fn"}   Netherland   prospective     3595              320                 Any                  n.s.             15                   CTA
  Tolia 2005\[[@pone.0170600.ref029]\]                                                USA          retrospective   83                16                  Any                  2                30                   CTA
  Sheehan 2006\[[@pone.0170600.ref030]\]                                              USA          retrospective   1909              221                 Any                  101              36                   CTA
  Silverberg 2006\[[@pone.0170600.ref031]\]                                           USA          retrospective   965               154                 Any                  19               22                   CTA
  Jones 2007\[[@pone.0170600.ref008]\]                                                USA          retrospective   873               164                 Any                  16               38                   CTA
  Abularrage 2010\[[@pone.0170600.ref009]\]                                           USA          retrospective   832               136                 Persistent           39               34.8                 CTA
  Brountzos 2012\[[@pone.0170600.ref010]\]                                            Greece       retrospective   136               31                  Persistent           n.s.             13.5                 CTA
  Koole 2012\[[@pone.0170600.ref032]\][\*](#t001fn001){ref-type="table-fn"}           Netherland   prospective     8638              4518                Any                  661              26                   CTA
  Nolz 2012\[[@pone.0170600.ref033]\]                                                 Austria      retrospective   407               49                  Any                  20               n.s.                 CTA
  Batti 2013\[[@pone.0170600.ref034]\]                                                France       prospective     700               201                 Any                  30               31.3                 CTA
  Chang 2013\[[@pone.0170600.ref035]\]                                                USA          retrospective   1736              474                 Any                  251              32.4                 CTA
  Jouhannet 2013\[[@pone.0170600.ref036]\]                                            France       retrospective   232               94                  Any                  14               23                   CTA
  Cieri 2014\[[@pone.0170600.ref037]\]                                                Italy        prospective     1412              218                 Any                  52               45                   CTA
  Maeda 2014\[[@pone.0170600.ref011]\]                                                Japan        retrospective   469               111                 Any                  n.s.             21.0                 CTA
  Sidloff 2014\[[@pone.0170600.ref038]\]                                              UK           prospective     904               175                 Any                  9                43.2                 DUS
  Ward 2014\[[@pone.0170600.ref039]\]                                                 USA          retrospective   326               99                  Any                  n.s.             n.s.                 CTA
  Dudeck 2015\[[@pone.0170600.ref040]\]                                               Germany      retrospective   188               62                  Any                  n.s.             39                   CTA
  Hiraoka 2015\[[@pone.0170600.ref041]\]                                              Japan        retrospective   148               36                  Any                  n.s.             28.8                 CTA
  Löwenthal 2015\[[@pone.0170600.ref042]\]                                            Germany      retrospective   130               62                  Any                  n.s.             22                   CTA
  Müller-Wille 2015\[[@pone.0170600.ref043]\]                                         Germany      retrospective   384               56                  Any                  20               36                   CTA
  Gallitto 2015\[[@pone.0170600.ref044]\]                                             Italy        prospective     200               47                  Any                  6                22                   CTA
  Kray 2015\[[@pone.0170600.ref045]\]                                                 USA          retrospective   191               18                  Any                  n.s.             n.s.                 CTA
  Nolz 2015\[[@pone.0170600.ref046]\]                                                 Austria      retrospective   143               69                  Any                  n.s.             n.s.                 CTA
  Pini 2015\[[@pone.0170600.ref047]\]                                                 Italy        retrospective   753               85                  Any                  2                19                   CTA/DUS
  Walker 2015\[[@pone.0170600.ref048]\]                                               USA          retrospective   1736              474                 Any                  111              32.2                 CTA
  Rousié 2015\[[@pone.0170600.ref049]\]                                               Belgium      retrospective   77                17                  Any                  0                79                   CTA
  Phan 2015\[[@pone.0170600.ref050]\]                                                 Germany      retrospective   82                51                  Any                  13               29.5                 CTA
  Piazza 2016\[[@pone.0170600.ref051]\]                                               USA          prospective     126               34                  Any                  7                16                   CTA
  Lo 2016\[[@pone.0170600.ref052]\]                                                   USA          retrospective   2367              807                 Persisent            n.s.             15.4                 n.s.
  Mursalin 2016\[[@pone.0170600.ref053]\]                                             Japan        retrospective   145               47                  Any                  n.s.             n.s.                 CTA
  Ikoma 2016\[[@pone.0170600.ref054]\]                                                Japan        prospective     34                12                  Any                  n.s.             n.s.                 CTA
  Pippin 2016\[[@pone.0170600.ref055]\]                                               USA          retrospective   163               66                  Any                  4                24.7                 CTA
  Fujimura 2016\[[@pone.0170600.ref056]\]                                             Japan        retrospective   832               234                 Any                  11               35.6                 CTA/MRI

\*Three papers were published from the EUROSTAR registry and may present duplicated data.

n.s., Not stated.

Prevalence of type II endoleaks after EVAR {#sec012}
------------------------------------------

A total of 9,654 type II endoleaks were reported to have occurred over a range of 12--79 follow-up months in 36,588 patients. The pooled prevalence of type II endoleaks after EVAR was 22% (95%CI, 19%--25%) ([Fig 2](#pone.0170600.g002){ref-type="fig"}). Reintervention for type II endoleaks was reported in 1466 (19%) of 7885 patients. The proportion of type II endoleaks was significantly greater in subgroups of studies published after 2010 \[13%, 95% CI (11%--16%) vs. 27% 95% CI (24%--31%)\] ([Table 2](#pone.0170600.t002){ref-type="table"}). The proportion of type II endoleaks was similar in subgroups of studies using CTA as surveillance test with those using others \[21%, 95% CI (14%--23%) vs. 24%, 95% CI (14%--34%)\]. The proportion of type II endoleaks was similar in subgroups of prospective studies with retrospective studies \[18%, 95% CI (15--21%) vs. 23%, 95% CI (19%--27%)\].

![Pooled prevalence of type II endoleaks after EVAR.](pone.0170600.g002){#pone.0170600.g002}

10.1371/journal.pone.0170600.t002

###### Subgroup analysis for prevalence of Type II endoleak.

![](pone.0170600.t002){#pone.0170600.t002g}

  Study subgroup      No. of studies   Total no. of participants   Pooled prevalence   95% CI       I^2^
  ------------------- ---------------- --------------------------- ------------------- ------------ ------
  Total               45               36588                       0.22                0.19--0.25   98.0
  Year of the study                                                                                 
  2001--2010          18               13929                       0.13                0.11--0.16   95.1
  2011--2016          27               22659                       0.27                0.24--0.31   97.5
  Study setting                                                                                     
  Prospective         10               15966                       0.18                0.15--0.21   96.1
  Retrospective       35               20622                       0.23                0.19--0.27   98.3
  Surveillance test                                                                                 
  CTA                 40               31672                       0.21                0.19--0.24   97.6
  Others              5                4916                        0.24                0.14--0.34   98.4

Meta-analysis of possible factors associated with type II endoleak {#sec013}
------------------------------------------------------------------

In total, eight studies reported on the effect of age on type II endoleaks ([Table 3](#pone.0170600.t003){ref-type="table"}). These studies consistently demonstrated that age was a risk factor for the onset of type II endoleaks, although considerable heterogeneity was present among the results reported (I^2^ = 99.0%). The pooled OR of the eight studies was 0.37 (95% CI, 0.31--0.43; P\<0.001). Twelve studies investigated smoking as a risk factor for the onset of type II endoleaks. Among these 14 studies, a considerable heterogeneity was observed between the study findings (I^2^ = 86.4%); however, all studies were generally consistent in reporting smoking as a protective factor for the onset of type II endoleaks. The pooled OR of the 12 studies was 0.71 (95% CI, 0.55--0.92; P\<0.001).

10.1371/journal.pone.0170600.t003

###### Pooled ORs for association of commonly studied risk factors with Type II endoleak.

![](pone.0170600.t003){#pone.0170600.t003g}

  Potential risk factors                   No. of studies   Total no. of participants   Pooled OR   95% CI       P value   I^2^
  ---------------------------------------- ---------------- --------------------------- ----------- ------------ --------- ------
  Age                                      8                6278                        0.37        0.31--0.43   \<0.001   99.0
  Male                                     12               11775                       0.83        0.67--1.02   0.059     46.4
  Smoking                                  14               20477                       0.71        0.55--0.92   \<0.001   86.4
  Diabetes                                 10               7303                        0.91        0.76--1.09   0.251     20.9
  Hypertension                             10               7281                        0.98        0.85--1.12   0.484     0
  Hyperlipidemia                           7                5522                        1.12        0.83--1.49   0.814     74.7
  Chronic renal insufficiency              10               9201                        0.85        0.53--1.36   0.600     85.3
  COPD                                     10               5745                        0.84        0.69--1.03   0.135     34.1
  Polytrafluoroethylene-based endografts   7                8396                        0.88        0.65--1.18   0.390     70.8
  Anticoagulants                           5                3758                        1.27        0.97--1.67   0.537     0
  Antiplatelet                             5                3758                        1.09        0.79--1.51   0.220     65.6
  Patent IMA                               3                4353                        1.98        1.06--3.71   0.012     77.6
  Number of patent lumbar arteries         2                758                         3.07        2.81--3.33   \<0.001   99.8
  Maximum aneurysm diameter                7                4858                        0.23        0.17--0.30   \<0.001   98.0

Seven cohort studies assessed the effect of maximum aneurysm diameter on the onset of type II endoleaks. The I^2^ among the seven studies was 98.0%, and the resulting pooled OR was 0.23 (CI, 0.17--0.30; P = 0.012), showing an increased risk of type II endoleaks in patients with a greater diameter of AAA. Three studies were included in the meta-analysis of patent IMA as a risk factor for the onset of type II endoleaks. The extent of heterogeneity present between the findings reported was considerable (I^2^, 77.6%), and the pooled OR was 1.98 (95% CI, 1.06--3.71; P\<0.001). Two studies reported the effect of number of patent lumbar arteries on type II endoleaks, and the pooled OR was 3.07 (95% CI, 2.81--3.33; P\<0.001).

Twelve studies assessed male sex as a potential risk factor. The pooled OR of 0.83 (95% CI, 0.67--1.02; I^2^, 46.4%) suggests that male sex is not associated with type II endoleaks. Diabetes (OR 0.91; 95% CI, 0.76--1.09), hypertension (OR, 0.98; 95% CI, 0.85--1.12), Polytrafluoroethylene-based endografts (OR, 0.88; 95% CI, 0.65--1.18), anticoagulants (OR, 1.27; 95% CI, 0.97--1.67), antiplatelet (OR, 1.09; 95% CI, 0.79--1.51), hyperlipidemia (OR, 1.12; 95% CI, 0.83--1.49), chronic renal insufficiency (OR, 0.85; 95% CI, 0.53--1.36), and COPD (OR, 0.84; 95% CI, 0.63--1.03) are not risk factors of type II endoleaks ([Table 3](#pone.0170600.t003){ref-type="table"}).

Sensitivity analyses by quality (methodological quality \>6), and sample size (n\>100) were done for the enrolled studies. All meta-analytic conclusions remained robust to this testing. The results of Begg's test (p = 0.432) and Egger's test (p = 0.338) revealed no significant publication bias in this study.

Discussion {#sec014}
==========

Endoleaks are specific complications of EVAR. Type II endoleaks are the most common type of endoleaks, occurring in approximately 10% of patients after EVAR \[[@pone.0170600.ref007]\]. Although Type II endoleaks are less likely to require secondary reintervention than type I or III endoleaks because of the possibility of arterial rupture \[[@pone.0170600.ref009]\], type II endoleaks are a risk factor for aneurysm sac growth, and ruptures occur in approximately 1% of patients with type II endoleaks after EVAR \[[@pone.0170600.ref007]\]. Thus, patients need continuous surveillance after EVAR to detect aneurysm growth and endoleaks. Previous studies explored risk factors for type II endoleaks after EVAR \[[@pone.0170600.ref009]--[@pone.0170600.ref011]\]. However, controversies have been found between these studies. These discrepancies may be attributed to the insufficient statistical power of individual studies and the inability to perform separate analyses. Therefore, we conducted a systematic review and meta-analysis to identify the risk factors for type II endoleaks after EVAR. Furthermore, the pooled prevalence of type II endoleaks must be updated on the basis of the latest evidence.

Among the potential risk factors for type II endoleaks, older age, patent inferior mesenteric artery, number of patent lumbar arteries, and maximum aneurysm diameter significantly increase the risk for type II endoleaks after EVAR. By contrast, smoking is a protective factor for type II endoleaks. Sex, diabetes, hypertension, anticoagulants, hyperlipidemia, chronic renal insufficiency, COPD, and polytrafluoroethylene-based endografts are not associated with the onset of type II endoleaks. To the best of our knowledge, this systematic review and meta-analysis is the first to identify the risk factors of type II endoleaks after EVAR. This paper also revealed a higher prevalence of type II endoleaks after EVAR compared with an earlier review \[[@pone.0170600.ref007]\]. Most of the included studies exhibited high methodological quality on the basis of the Newcastle--Ottawa scale. Statistical tests were performed to examine the issue of publication bias, and results revealed no statistically significant publication bias.

Sidloff et al. \[[@pone.0170600.ref007]\] performed a systematic review that included 22 studies to evaluate the prevalence of type II endoleaks. A total of 1,515 type II endoleaks were reported to have occurred in 14,794 patients (10.2%). In this study, 9,654 of 36,588 patients developed type II endoleaks after 12--45 months of follow-up (26.4%). The proportion of type II endoleaks was significantly greater in the subgroup analysis of studies published after 2010 compared with those published before 2010 (27% vs. 13%). These results may be attributed to the improved accuracy of imaging tools for the surveillance after EVAR, more endoleaks might be detected by the upgraded imaging tools.

Reintervention for type II endoleaks has been reported in 1,466 (19%) of 7,885 patients. Management of type II endoleaks is still debated because clinical outcomes vary in published literature \[[@pone.0170600.ref034],[@pone.0170600.ref036],[@pone.0170600.ref037],[@pone.0170600.ref044]\]. Some studies have indicated that persistence of type II endoleaks is not a negligible complication that could require re-interventions and decrease the long-term EVAR success \[[@pone.0170600.ref044]\]. Moreover, the endovascular reinterventions for type II endoleaks associated with an enlargement of the aneurysmal sac after EVAR have a poor effectiveness on the stabilization of the diameter of the AAA \[[@pone.0170600.ref036]\]. Other studies stated that recurrent and persistent type II endoleaks are prone to life-threatening complications, and type II endoleak appears to be a marker of EVAR failure that is difficult to predict and treat effectively \[[@pone.0170600.ref034],[@pone.0170600.ref037]\]. The debate about the indication of intervention for type II endoleaks seems to last.

From the anatomic aspect, we identified patent IMA, number of patent lumbar arteries, and maximum aneurysm diameter as risk factors for the onset of type II endoleaks. Preoperative embolization of the IMA has been proved to be associated with decreased risk of type-2 endoleak and aneurysm sac enlargement after EVAR \[[@pone.0170600.ref057]\]. Considering aneurysm diameter, it is likely that the increased flow channel within the aneurysm sac coupled with a larger number of patent aortic branch vessels leads to increased flow velocities within the sac, thus decreasing the likelihood of type II endoleak resolution \[[@pone.0170600.ref058]\]. It is reported that the number of patent lumbar arteries was also correlated with onset of type II endoleak, however, this study did not include the analysis because no other studies reported the similar issue \[[@pone.0170600.ref009]\].

In total, 12 studies investigated smoking as a risk factor for the onset of type II endoleaks. All studies were generally consistent in reporting smoking as a protective factor for the onset of type II endoleaks. Koole et al. \[[@pone.0170600.ref032]\] reported a study that analyzed the data of 8638 patients who were enrolled prospectively in the European Collaborators on Stent-Graft Techniques for Aortic Aneurysm Repair database. The study observed decreased intraoperative perfusion from the mesenteric inferior artery or lumbar arteries in smokers. The explanation of these findings remains unclear; however, we hypothesized that tobacco use can induce the atherosclerotic injury of medium- and small-sized vessels, which may narrow or occlude these arteries and thereby impair the blood flow \[[@pone.0170600.ref032]\]. There is also an increased tendency of coagulation in smokers, which also might narrow or occlude the arteries. We also found that older age is a risk factor for the onset of type II endoleaks. Long history and large diameter of AAA in aging patients, favoring high-pressure aneurysm sac, may be a possible explanation of this fact. Besides, aging patients might also have more severe atherosclerotic injury of vessels which induced impair of the retrograde flow into abdominal aorta.

Our review also has some limitations. First, only the main predictors drawn from the articles were analyzed because of data deficiencies. Second, our study was subjected to heterogeneity in some of the inclusion criteria, as well as relatively small sample sizes and numbers of articles, which may have caused potential publication bias. Only three studies were included in the meta-analysis of patent IMA as a risk factor for the onset of type II endoleaks, whereas only four studies provided data that compared the effects of anticoagulants used on the onset of type II endoleaks. Furthermore, most of the articles included in our review are retrospective observational studies. A long-term prospective study to specifically define risk factors of endoleaks would be instructive.

In conclusion, age, patent inferior mesenteric artery, number of patent lumbar arteries, maximum aneurysm diameter, and non-tobacco use are significant factors in predicting type II endoleaks. Meanwhile, sex, diabetes, hypertension, anticoagulants, antiplatelet, hyperlipidemia, chronic renal insufficiency, types of graft material, and COPD show no statistical significance. Thus, clinicians should pay attention to these factors in AAA patients after EVAR.
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